Focus: Xilio Therapeutics is a Waltham-based cancer immunotherapy biotech focused on advancing novel oncology treatments through early-stage clinical development. The company operates as a public-stage biotechnology firm with a concentrated pipeline in solid tumors and NSCLC.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Xilio offers exposure to cutting-edge cancer immunotherapy R&D but suits risk-tolerant candidates comfortable with early-stage clinical risk and minimal near-term hiring.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Xilio Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Xilio Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates TradingKey
XLO|Xilio Therapeutics Inc|Price:9.110|Chg%:+0.030 - TradingKey
XLO|Xilio Therapeutics Inc|Price:9.110|Chg%:+0.030 TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk TradingKey
Xilio Therapeutics Inc (XLO) Income Statement - TradingKey
Xilio Therapeutics Inc (XLO) Income Statement TradingKey
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo